Newton Valerio Verbisck

Dr. Newton Valerio Verbisck

Embrapa Beef Cattle, Campo Grande, Mato Grosso do Sul, Brazil
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2003 in Oncogene
Verified
Journal Article
Closed access
PDF file
FCFabrício F Costa
Fabrício F Costa
Newton Valerio VerbisckNewton Valerio Verbisck
Newton Valerio Verbisck
ASAnna Christina M Salim
Anna Christina M Salim
DIDaniela F Ierardi
Daniela F Ierardi
LPLilian C Pires
Lilian C Pires
ACAnamaria Camargo
Anamaria Camargo

1 July 2009 in Cancer Research
Verified
Journal Article
Open access
PDF file
Newton Valerio VerbisckNewton Valerio Verbisck
Newton Valerio Verbisck
ECÉrico T. Costa
Érico T. Costa
FCFabrício F. Costa
Fabrício F. Costa
FCFelícia P. Cavalher
Felícia P. Cavalher
MCMichele D.M. Costa
Michele D.M. Costa
ACAnamaria Camargo
Anamaria Camargo
The ADAM23 gene is frequently silenced in different types of tumors, and, in breast tumors, silencing is correlated with tumor progression, suggesting that it might be associated with the acquisition of a metastatic phenotype. ADAM23 exerts its function mainly through the disintegrin domain, because its metalloprotease domain is inactive. Analysis of ADAM23 binding to integrins has revealed a specific interaction with αvβ3 integrin mediated by the disintegrin domain. Altered expression of αvβ3 integrin has been observed in different types of tumors, and expression of this integrin in the activated form has been shown to promote metastasis formation. Here, we investigated the possibility that interaction between ADAM23 and αvβ3 integrin might negatively modulate αvβ3 activation during metastatic progression. ADAM23 expression was knocked down using short hairpin RNA in the MDA-MB-435 cell line, which has been extensively used as a model for αvβ3 integrin activation. Ablation of ADAM23 enhanced αvβ3 integrin activation by at least 2- to 4-fold and ADAM23 knockdown cells showed enhanced migration and adhesion to classic αvβ3 integrin ligands. Ablation of ADAM23 expression also enhanced pulmonary tumor cell arrest in immunodeficient mice. To complement our findings with clinical evidence, we showed that silencing of ADAM23 gene by DNA promoter hypermethylation in a collection of 94 primary breast tumors was significantly associated with lower distant metastases–free and disease-specific survivals and was an independent prognostic factor for poor disease outcome. Our results strongly support a functional role of ADAM23 during metastatic progression by negatively modulating αvβ3 integrin activation. [Cancer Res 2009;69(13):5546–52]

1 September 2019 in Biocatalysis and Agricultural Biotechnology
Verified
Journal Article
Closed access
PSPatricia Oliveira da Silva
Patricia Oliveira da Silva
NGNelciele Cavalieri de Alencar Guimarães
Nelciele Cavalieri de Alencar Guimarães
JSJohn Dayvan Maidana Serpa
John Dayvan Maidana Serpa
DMDouglas Chodi Masui
Douglas Chodi Masui
CMClarice Rossatto Marchetti
Clarice Rossatto Marchetti
GGGiovana Cristina Giannesi
Giovana Cristina Giannesi

1 July 1997 in Journal of Eukaryotic Microbiology
Verified
Journal Article
Closed access
PDF file
HBHelena C. Barros
Helena C. Barros
Newton Valerio VerbisckNewton Valerio Verbisck
Newton Valerio Verbisck
SSSolange DA Silva
Solange DA Silva
MAMarcia F. Araguth
Marcia F. Araguth
RMRenato A Mortara
Renato A Mortara

31 January 2018 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
SRSuellen Rodrigues Ramalho
Suellen Rodrigues Ramalho
CBCézar da Silva Bezerra
Cézar da Silva Bezerra
DODaniella Gorete Lourenço de Oliveira
Daniella Gorete Lourenço de Oliveira
LLLetícia Souza Lima
Letícia Souza Lima
SNSimone Maria Neto
Simone Maria Neto
MMMaria Ligia Macedo
Maria Ligia Macedo

7 June 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
BFBreno Emanuel Farias Frihling
Breno Emanuel Farias Frihling
ABAna Paula de Araújo Boleti
Ana Paula de Araújo Boleti
Caio Fernando Ramalho de OliveiraCaio Fernando Ramalho de Oliveira
Caio Fernando Ramalho de Oliveira
SSSimone Sanches
Simone Sanches
PCPedro Henrique de Oliveira Cardoso
Pedro Henrique de Oliveira Cardoso
Ludovico MiglioloLudovico Migliolo
Ludovico Migliolo
Nature presents a wide range of biomolecules with pharmacological potential, including venomous animal proteins. Among the protein components from snake venoms, phospholipases (PLA2) are of great importance for the development of new anticancer compounds. Thus, we aimed to evaluate the PLA2 anticancer properties from Bothrops moojeni venom. The crude venom was purified through three chromatographic steps, monitored by enzymatic activity and SDS-PAGE (12%). The purified PLA2 denominated BmPLA2 had its molecular mass and N-terminal sequence identified by mass spectrometry and Edman degradation, respectively. BmPLA2 was assayed against human epithelial colorectal adenocarcinoma cells (Caco-2), human rhabdomyosarcoma cells (RD) and mucoepidermoid carcinoma of the lung (NCI-H292), using human fibroblast cells (MRC-5) and microglia cells (BV-2) as a cytotoxicity control. BmPLA2 presented 13,836 Da and a 24 amino acid-residue homologue with snake PLA2, which showed a 90% similarity with other Bothrops moojeni PLA2. BmPLA2 displayed an IC50 of 0.6 µM against Caco-2, and demonstrated a selectivity index of 1.85 (compared to MRC-5) and 6.33 (compared to BV-2), supporting its selectivity for cancer cells. In conclusion, we describe a new acidic phospholipase, which showed antitumor activity and is a potential candidate in the development of new biotechnological tools.